In 2025, the precision cancer imaging market was valued at USD 6,473.8 million. Based on Future Market Insights' analysis, demand is estimated to grow to USD 6,907.5 million in 2026 and USD 13,212.0 million by 2036. FMI projects a CAGR of 6.7% during the forecast period.
Absolute dollar growth of USD 6,304.4 million over the decade reflects a structural shift toward AI-integrated imaging platforms that reduce diagnostic turnaround time and improve tumour detection sensitivity. The integration of liquid biopsy with precision imaging, as demonstrated by the NHS's blood-test-first approach for suspected lung cancer, is creating new clinical pathways that rely on imaging confirmation of molecular findings. Helium-free MRI systems and AI-powered scan acceleration are lowering per-scan operating costs, expanding imaging access in resource-constrained settings.
As Nathan Clark, CCO of Quibim, stated regarding the launch of QP-Prostate at RSNA 2025, 'QP-Prostate has evolved into a fully integrated ecosystem, combining advanced 3D visualization with seamless workflow connectivity.' [1]
The United States (7.2% CAGR) leads through Medicare-covered cancer screening programmes and AI-diagnostic reimbursement expansion. Germany (6.5% CAGR) grows through academic research institute investment and European consortium funding such as PreciseOnco. Japan (6.0% CAGR) benefits from national cancer screening mandates and imaging equipment manufacturing. China (7.8% CAGR) is the fastest-growing market, driven by hospital imaging department expansion and AI-diagnostic platform adoption. India (7.0% CAGR) benefits from public hospital infrastructure investment.
The precision cancer imaging market covers the sale, installation, and clinical use of advanced imaging systems and AI-powered software platforms used for cancer diagnosis, treatment planning, treatment monitoring, and recurrence detection. The market includes MRI, CT, PET/CT, PET/MRI, ultrasound, and molecular imaging modalities when applied to oncology.
The report covers global and regional market sizes by revenue for the 2026 to 2036 forecast period. It includes segmental breakdowns by modality, application, and end use. AI software licensing revenue, imaging equipment pricing, and clinical trial pipeline tracking are included.
The scope excludes general-purpose diagnostic imaging not applied to oncology. It also omits laboratory-based pathology and genomic testing unless integrated with imaging workflows. Imaging contrast agents and radiopharmaceuticals are outside scope unless bundled with imaging system procurement.
Primary Research: Interviews were conducted with radiologists, oncologists, hospital imaging department directors, AI-diagnostic software developers, and imaging equipment procurement managers across the United States, Europe, Japan, and China.
Desk Research: FDA AI/ML medical device approval databases, CE marking registrations, clinical trial registries, national cancer screening programme statistics, and hospital imaging equipment installation data supported demand benchmarking.
Market-Sizing and Forecasting: A hybrid model combined top-down cancer incidence and screening volume analysis with bottom-up imaging equipment installed base and AI software licensing revenue, validated against manufacturer annual reports.
Data Validation and Update Cycle: Outputs undergo anomaly screening, variance checks across cancer incidence and imaging procedure volume datasets, and structured peer review prior to release.
Power in the precision cancer imaging value chain is concentrated among three global imaging OEMs: Siemens Healthineers, GE HealthCare, and Philips. These companies control the installed base of MRI, CT, and PET/CT systems in hospitals and imaging centres, and are now integrating AI-powered diagnostic software into their platforms to create switching-cost barriers. As per FMI, AI-diagnostic startups such as Quibim and Paige face the challenge of achieving hospital IT integration without direct control of the imaging hardware layer.
Pricing asymmetry reflects the hardware-to-software value shift. A hospital-grade 3T MRI system costs USD 1.5 to 3 million, while an AI-powered tumour detection software licence adds USD 50,000 to 200,000 per year but can reduce diagnostic turnaround by 30 to 50%. FMI analysts note that the software component carries gross margins above 70%, compared to 25 to 35% for imaging hardware, making AI integration the primary margin expansion strategy for OEMs.
Sourcing fragility centres on helium supply for MRI systems and AI training data availability. Conventional MRI magnets require liquid helium cooling, and global helium supply is concentrated in fewer than five production facilities. Philips' helium-free BlueSeal magnet technology addresses this constraint but is not yet universally adopted. AI model training requires large, annotated cancer imaging datasets that are subject to patient privacy regulations and institutional data-sharing agreements.
Brand and compliance risks are tied to AI-diagnostic regulatory approval and clinical liability. The FDA has cleared over 500 AI/ML-enabled medical devices, but oncology-specific AI diagnostics face heightened scrutiny due to the clinical consequences of false negatives. FMI opines that imaging OEMs and AI developers who invest in prospective clinical validation trials will achieve faster regulatory clearance and broader hospital adoption than those relying on retrospective data alone.
Geographic leverage differs by healthcare system structure. The United States leads in AI-diagnostic reimbursement and clinical trial infrastructure. Europe is consortium-funded, with projects like PreciseOnco (EUR 23.9 million) driving minimally invasive imaging-guided treatment development. Japan has the highest per-capita MRI installed base. China is the volume growth engine, with hospital imaging department construction outpacing trained radiologist supply, creating demand for AI-assisted interpretation.
For C-suite executives in medical imaging and healthcare IT, the precision cancer imaging market through 2036 rewards companies that build AI-software platforms on top of installed imaging hardware bases, secure regulatory clearance for oncology-specific algorithms, and integrate liquid biopsy data with imaging findings to create multi-modal diagnostic workflows.
Comparative analysis of fluctuations in compound annual growth rate (CAGR) for the global precision cancer imaging market between 2024 and 2025 on six months basis is shown below. By this examination, major variations in the performance of these markets are brought to light, and also trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market's growth path in any other given year. January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December
The table presents the expected CAGR for the global precision cancer imaging market over several semi-annual periods spanning from 2025 to 2036. In the first half (H1) of the decade from 2026 to 2036, the business is predicted to surge at a CAGR of 7.4%, followed by a slightly slower growth rate of 7.1% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.4% (2021 to 2025) |
| H2 | 7.1% (2021 to 2025) |
| H1 | 6.7% (2026 to 2036) |
| H2 | 6.2% (2026 to 2036) |
Moving into the subsequent period, from H1 2026 to H2 2036, the CAGR is projected to decrease slightly to 6.7% in the first half and decrease moderately at 6.2% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Strategic Initiatives taken by Authorities for Cancer Imaging Surges Market Growth
Authorities and healthcare organizations play a strategic role in driving the growth of the precision cancer imaging market through initiatives that aim to improve cancer diagnosis and treatment outcomes.
Investments made by government in initiatives like the Cancer Moonshot in the USA and European Union's Horizon programs foster innovation in imaging technologies, molecular imaging, and hybrid imaging systems. These programs aim to accelerate the development and adoption of precision cancer imaging to reduce cancer mortality through early detection and personalized care.
The FDA and EMA provide streamlined approval for new imaging technologies and agents. The policies for cooperation between the academia, developers of technology, and healthcare providers ensure access to innovative imaging equipment. Reimbursement reforms in place to incentivize the application of precision imaging in clinical settings boost adoption.
Awareness campaigns and screening programs introduced by cancer societies and health authorities further increase the demand. The synergy of all these strategic efforts is to support innovation, accessibility, and the general diffusion of precision cancer imaging.
Integration of Advanced Imaging Technologies in Precision cancer Imaging contribute to its Increased Adoption Rate
Advanced imaging technologies integrated into precision cancer imaging have a great effect on increasing the adoption rate of precision cancer imaging, enhancing diagnostic accuracy, efficiency, and personalization of cancer care. Newer technologies involving AI, machine learning, and hybrid imaging systems further enhance image analysis and give detailed insight into tumor characteristics that are crucial for early detection and tailored treatment strategies.
Use of AI-powered tools automate image interpretation, by reducing diagnostic errors, enabling faster, and more consistent assessments. In addition, growing adoption of hybrid imaging modalities, such as PET-CT and PET-MRI, when used in combination, it offers comprehensive information about the location of cancer tumors, which aid healthcare professionals in analysing its metabolism, and molecular activity.
This holistic approach minimizes the need for multiple procedures, saving healthcare costs and patient burden.
Moreover, digital imaging platforms and cloud-based solutions are continuously improving in order to share and collaborate on data among healthcare teams more smoothly, which quickens decision-making. These technology enhancements in workflow, patient experience, and treatment outcomes are driving the wide adoption of precision cancer imaging into clinical practice. Advanced technologies make precision imaging indispensable in modern oncology by offering superior diagnostic capabilities.
Emphasis on Introduction of Hybrid Imaging Modalities bring Growth Opportunities to Players in Precision Cancer Imaging
Hybrid imaging technologies combine functional and anatomical imaging in one system with an extended view of cancerous tissues, such as PET-CT, PET-MRI, and SPECT-CT.
These imaging modalities enable precise tumor localization and detailed insights into metabolic and molecular activity, thus allowing for early detection, accurate staging, and personalized treatment planning. The increasing demand for integrated approaches to diagnosis in the management of complex cancer cases is driving the demand for these value-added solutions.
These hybrid systems tend to reduce the number of diagnostic procedures a patient undergoes, thus minimizing discomfort and health costs. Many hospitals and diagnostic centers continue investing in such technologies due to enhanced efficiency in patient care, which makes this a very lucrative market for the manufacturers.
This is further being developed with compact, affordable systems and the integration of artificial intelligence to enhance image interpretation. Companies that focus on developing innovative hybrid imaging platforms can capture substantial market share by addressing these evolving needs, expanding their reach, and driving growth in precision cancer imaging.
High Cost Associated with Precision Cancer Imaging Technologies Attributes to its Slower Adoption in Developing Economies
Highly advanced imaging devices like PET-CT, PET-MRI, and molecular imaging require large investments for equipment procurement, installation, and maintenance. In addition, special agents used for imaging and AI-based diagnostic software contribute to operational costs, thus becoming expensive for many healthcare organizations.
In developing regions, where healthcare infrastructure is often limited with funds, hospitals and diagnostic centers opt for cost-effective solutions over advanced, high-cost technologies. Imaging modalities such as X-rays and ultrasound, are often preferred over the advanced, and high-cost technologies as they are cheaper and easier to maintain.
Moreover, the high cost of procedural care related to high-precision imaging result in out-of-pocket expenditures for the patient, leading to reduced use, particularly in low-income countries. The poorly developed reimbursement infrastructure adds to the problem because the health systems in developing countries fail to reimburse advanced imaging completely.
Investments in the training programs for radiologists and technicians are also affected by the cost barrier, which consequently lowers the skilled personnel required for running complex imaging systems. Therefore, these hurdles must be bridged by technological advances in reducing equipment costs, by the government subsidy for healthcare technology, and reforms in policies concerning better reimbursement structures.
The global precision cancer imaging industry recorded a CAGR of 6.7% during the historical period between 2021 and 2025. The growth of precision cancer imaging industry was positive as it reached a value of USD 6,002.0 million in 2026 from USD 4,810.1 million in 2036.
Precision cancer imaging in oncology defines the transformed use of advanced imaging toward enhancing diagnosis, treatment planning, and follow-up care in cancer. It epitomizes the integration of anatomical, functional, and molecular imaging methods that give detailed insight into the characteristics of tumors for personalized care in cancer.
The increasing incidence of cancer attribute to the raising demands for sophisticated diagnostic solutions that enhance early detection and precision in treatment. Technological development, including AI and machine learning, automates image analysis, thereby enhancing diagnostic accuracy while reducing interpretation errors. Growing focus on personalized medicine is further boosting the adoption of advanced imaging modalities for treatment plans tailored to tumor biology.
Recent technological advancements such as hybrid imaging modalities combine functional and structural information and provide a holistic view of tumor characteristics. Furthermore, integration of AI radiomics and machine learning algorithms further enhance image processing.
From a future perspective, additional investments in AI tools, molecular tracers, and portable systems are estimated to continue to drive market growth. Expansion of healthcare infrastructure and government initiatives related to cancer screening in developing regions further projected to anticipate the market growth. Moreover, reforms in reimbursement policies and regulatory support for new technologies accelerate the adoption.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 64.6% in global market. These market leaders are characterized by high production capacity and a wide product portfolio. These market leaders are distinguished by their extensive expertise in manufacturing and reconditioning across multiple packaging formats and a broad geographical reach, underpinned by a robust consumer base. Prominent companies within tier 1 include GE Healthcare Ltd., Koninklijke Philips N.V. and Siemens Healthineers
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 26.7% market share. These are characterized by a strong presence overseas and strong market knowledge. These market players have good manufacturing technology and ensure regulatory compliance but may not have access to global reach. Prominent companies in tier 2 include Hologic, Inc., Hitachi, Ltd., and Shimadzu Corporation
Finally, Tier 3 companies, act as a suppliers to the established market players. They are essential for the market as they specialize in specific products and cater to niche markets, adding diversity to the industry.
Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the precision cancer imaging market remains dynamic and competitive.
The section below covers the industry analysis for the precision cancer imaging market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with a value share of 59.7% through 2035. In Asia Pacific, South Korea is projected to witness a CAGR of 5.8% by 2034.
| Country | Value CAGR (2026 to 2036) |
|---|---|
| UK | 5.4% |
| China | 5.6% |
| Japan | 5.0% |
| South Korea | 5.8% |
| Germany | 4.3% |
| India | 3.8% |
| GCC Countries | 2.4% |
USA precision cancer imaging market is poised to exhibit a CAGR of 6.4% between 2025 and 2035. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
In the United States, the expansion of cancer screening programs together with more favorable reimbursement policies acts as a stimulus for precision cancer imaging. Different national programs initiated for screening breast, lung, and colorectal cancers create demand for more sophisticated imaging, which comes out with improved diagnostic accuracy and detection at earlier stages.
Advanced diagnostic capabilities through modalities, like low-dose computed tomography of the lungs or digital mammography, make this kind of imaging more personalized to individual patient features and, if found early, result in treatable stages.
Favorable reimbursement policies further boost this adoption by making these advanced procedures more accessible. Coverage by Medicare and private insurers increases to cover the costs associated with precision imaging; thus, lowering the financial burden on healthcare providers and patients. These extended programs for screening and supportive reimbursement frameworks advocate innovation and adoption, putting precision imaging as a cornerstone in modern oncology care in the United States.
Japan is anticipated to grow at a substantial CAGR of 5.0% throughout the forecast period.
The Japanese market promises remarkable growth due to the emergent innovative progress in precision cancer imaging. Hybrid imaging modality innovation-like PET-CT and PET-MRI-perfectly integrate anatomical-functional data to elevate diagnostic precision for exact tumor localization and characterization. Japan leads in the development of molecular imaging agents of advanced generation with specific targets among cancer biomarkers, reinforcing the reasons of early detection and personalized treatment planning.
Artificial intelligence and machine learning developments are automating image analysis and increasing diagnostic efficiency, thus transforming cancer imaging in Japan.
Moreover, the development of portable and point-of-care imaging devices extends precision diagnostics to rural and underserved areas. The continuous development of radiation dose reduction techniques improves patient safety and further encourages the adoption of imaging technologies.
Support for research and development by the government, apart from favorable regulatory frameworks, further enables environment for innovation. With such ceaseless strides in technology, the precision cancer imaging market of Japan is set for accelerated growth that promises improved patient outcomes and place it at the lead in oncology diagnostics.
Germany is expected to have a strong foothold when it comes to technology innovation. In 2023 the country is projected to account for substantial share of the precision cancer imaging market.
Precision imaging techniques such as PET-CT, PET-MRI, and molecular imaging provide an in-depth analysis of tumor. It analyzes its size and location along with its metabolic activity in the patient’s body.
The incidence rates of age-related cancers, including breast, lung, and colorectal cancer has increased significantly in Germany, owing to the growing population. This factors further contributes to a greater demand for higher sensitivity and specific imaging technologies.
Precision imaging allows for far better survival through early diagnosis facilitated by the possibility of detecting malignancy at stages much more amenable to treatment.
Government and healthcare initiatives on cancer screening and personalized medicine further amplify the adoption of precision imaging. The programs for screening of breast and lung cancers are increasingly using technologies that integrate functional and molecular imaging for accuracy. Furthermore, the increasing burden of cancer is encouraging continued investment in research and innovation to develop cost-effective and safer imaging solutions.
With the incidence of cancer continuing to rise, precision imaging in comprehensive cancer care will gain much importance, thereby driving market growth in Germany.
The section contains information about the leading segments in the industry. By technique, CT-based navigation system segment hold highest share of the market.
| Imaging Technique | Value Share (2026) |
|---|---|
| Molecular Imaging | 46.4% |
Molecular imaging, has ability to visualize cellular processes and tumor-specific biomarkers, which is dominant in precision cancer imaging beyond functional imaging of structural imaging. Techniques such as PET, is often combined with computed tomography (PET-CT) or magnetic resonance imaging (PET-MRI), which aid in detection of metabolic activity that enables earlier detection and accurate staging of cancer.
These technique enables accurate tumor characterization and treatment planning. Furthermore, its ability to monitor therapeutic responses and detect recurrence with high sensitivity reinforces personalized medicine. The incorporation of radiopharmaceuticals targeting specific cancer biomarkers further reinforces its position, making molecular imaging indispensable in modern diagnostics and personalized cancer treatment, which all together aid it to dominate the precision cancer imaging.
| End Use | Value Share (2036) |
|---|---|
| Hospitals | 58.4% |
The hospitals segment is forecast to account for a share of 58.4% and is poised to expand at a substantial CAGR during the forecast period.
The dominance of the hospital segment in precision cancer imaging is attributed to its access to advanced infrastructure, multidisciplinary expertise, and comprehensive patient care services. They play a central role in cancer diagnosis, treatment planning, and monitoring, integrating precision imaging into personalized oncology care. Apart from this, research collaborations and government funding facilitate the adoption of the latest advances in cancer imaging.
Moreover, hospitals form major centers for the screening of cancers and follow-up management of patients, thus keeping the demand for precision imaging technologies flowing. All these factors keep the hospital segment at the dominant position in the precision cancer imaging market due to critical services and advanced diagnostic solutions provided by them.
Substantial investments and focus is seen in the precision cancer imaging industry towards launch of new series of products to the market. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Developments
| Items | Values |
|---|---|
| Quantitative Units | USD 6,907.5 million (2026) to USD 13,212.0 million (2036), at a CAGR of 6.7% |
| Market Definition | Covers sale, installation, and clinical use of advanced imaging systems and AI-powered software platforms for cancer diagnosis, treatment planning, monitoring, and recurrence detection. |
| Modality Segmentation | MRI, CT, PET/CT, PET/MRI, Ultrasound, Molecular Imaging |
| Application Segmentation | Diagnosis, Treatment Planning, Treatment Monitoring, Recurrence Detection |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa |
| Countries Covered | United States, Germany, France, United Kingdom, Japan, China, India, South Korea, Australia, Brazil, Canada and 30 plus countries |
| Key Companies Profiled | Siemens Healthineers, GE HealthCare, Philips, Canon Medical Systems, Fujifilm, Hologic, Quibim, Paige, Heartflow, Medtronic |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid top-down and bottom-up modeling validated through primary interviews with radiologists, oncologists, and imaging equipment procurement managers |
In terms of Imaging Technique, the industry is divided into magnetic resonance imaging, molecular imaging and nuclear medicine scans
The industry is classified by end user as hospitals, research laboratories, diagnostic laboratories, academic research institutes and specialty clinics
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa (MEA) have been covered in the report.
How large is the precision cancer imaging market in 2026?
The global market is estimated at USD 6,907.5 million in 2026.
What will the market size be by 2036?
The market is projected to reach USD 13,212.0 million by 2036.
What is the expected CAGR?
Demand is expected to grow at a CAGR of 6.7% between 2026 and 2036.
Which modality leads?
MRI holds the largest modality share in oncology imaging, though PET/CT is the fastest-growing segment.
Which country is growing fastest?
China at 7.8% CAGR, driven by hospital imaging department expansion and AI-diagnostic adoption.
What is driving AI adoption?
Radiologist shortage, diagnostic turnaround requirements, and reimbursement pathway expansion for AI-assisted interpretation.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Precision Cancer Imaging Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
